AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Asia, China
ABSTRACT
Background: Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma with marked clinical heterogeneity. Although BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have improved outcomes, most patients ultimately relapse, underscoring the need to define resistance mechanisms, identify high-risk populations, and develop biomarker-guided therapeutic strategies. SP140 is an epigenetic reader recurrently altered in hematologic malignancies, but its role in BCL2 inhibitor response in MCL remains unclear. We investigated the role and mechanism of SP140 in regulating sensitivity to the BCL2 inhibitor venetoclax (VEN) and explored therapeutic strategies to overcome VEN resistance in SP140-deficient MCL.
Methods: Transcriptomic data from 134 MCL patients were analyzed to explore the function of SP140. Stable SP140 knockdown or overexpression cell lines were constructed in multiple MCL cell lines, and VEN-resistant cell lines (Z-138 R) was induced. The effects of SP140 on drug sensitivity and pathway alterations were evaluated in vitro and in vivo. RNA-seq, ATAC-seq, and ChIP-seq analyses were performed to identify SP140 downstream epigenetic targets, followed by functional perturbation studies. Protein–protein interactions were characterized by immunoprecipitation followed by mass spectrometry (IP–MS). Alternative splicing analyses, dual-luciferase reporter assays, and western blotting were used to investigate the splicing and translation of XIAP. The anti-MCL activity and mechanism of Eribulin monotherapy or combination therapy with VEN were evaluated in SP140 knockdown or Z-138 R cells in vitro and in vivo.
Results: SP140 deletion or mutation was associated with MCL progression and inferior survival in preliminary study involving WES of 134 MCL patient samples and RNA-seq of 62 MCL samples. Transcriptomic analyses further showed that SP140 deficiency was associated with enhanced mitochondrial programs and mitophagy. Functionally, SP140 knockdown reduced sensitivity to VEN monotherapy or combination therapy with ibrutinib both in vitro and in vivo. Analysis of shared upregulated genes across three SP140-knockdown MCL cell lines further revealed significant enrichment of microtubule polymerization/depolymerization pathways, suggesting increased dependence on microtubule dynamics following SP140 deficiency. To identify downstream effectors of SP140, we integrated ATAC-seq and RNA-seq data from SP140-knockdown Jeko-1 cells with RNA-seq data from SP140-deficient MCL patient samples, and prioritized genes with both increased chromatin accessibility and upregulated expression. This analysis identified three candidate targets, of which STMN3 emerged as the most compelling, consistent with the enrichment of microtubule dynamics–related pathways. SP140 downregulation was associated with increased chromatin accessibility at the STMN3 locus and reduced H3K27me3 modification, leading to upregulated STMN3 expression. STMN3 overexpression induced VEN resistance, whereas STMN3 knockdown restored drug sensitivity in both parental Z-138 and Z-138 VEN resistant cells. IP-MS analysis revealed that proteins interacting with STMN3 were enriched in RNA processing- and splicing–related functions. Under VEN stress, SP140 knockdown or STMN3 overexpression induced a specific XIAP exon-skipping event that generated a shorter 5′UTR transcript with enhanced translational efficiency, thereby sustaining XIAP protein expression, suppressing caspase-3 activation, and promoting VEN resistance. Mechanistically, we found for the first time that STMN3 also localized to the nucleus and interacted with splicing factors including DDX39A and PHF5A, suggesting that STMN3 participates in RNA splicing regulation.
Consistent with the microtubule dependency induced by SP140 deficiency, eribulin, a clinically available microtubule dynamics inhibitor, emerged as a mechanistically matched strategy to overcome SP140 deficiency–mediated VEN resistance. Eribulin also showed synergistic cytotoxicity with VEN and restored VEN sensitivity by disrupting microtubule cytoskeleton organization and cell-cycle progression.
Conclusions: SP140 deficiency promotes VEN resistance in MCL through the STMN3-XIAP splicing/translation axis and defines a microtubule-dependent vulnerable state. Eribulin synergizes with VEN and provides a rationale for biomarker-directed combination therapy in SP140-deficient MCL.
Keywords: Mantle cell lymphoma, SP140, BCL2 inhibitor, RNA splicing, drug resistance